Mesoblast submits new information to fda ind file in response to items in the crl to the remestemcel-l bla for sr-agvhd

New york, oct. 02, 2022 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that it has submitted to the u.s. food and drug administration (fda) substantial new information on clinical and potency assay items identified in the complete response letter (crl) received from fda in september 2020 to the biologics license application (bla) for remestemcel-l in the treatment of children with steroid-refractory acute graft versus host disease (sr-agvhd).
MESO Ratings Summary
MESO Quant Ranking